Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Marked and rapid drops in food intake and body weight seen with novel FAS inhibitor

July 14, 2000

New compounds interacting with NPY receptors useful for eating disorders, etc.

July 13, 2000

Metabolic disorder collaboration between BMS and Karo Bio extended

July 13, 2000

Novel cathepsin K inhibitors and their use in bone disorders patented

July 12, 2000

New Yissum compounds useful against oxidative stress or free radical injury

July 12, 2000

Axokine phase II obesity trial completes enrollment

July 11, 2000

Novel cystatin protein expressed in testis and potential uses thereof described by ZymoGenetics

July 11, 2000

Alizyme successfully concludes phase Ia trial of ATL-962 for treatment of obesity

July 11, 2000

Vasopressin V1a receptor antagonist aids in prevention of dysmenorrhea

July 11, 2000

Schering-Plough patents new group of vitronectin receptor antagonists

July 10, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...